569 related articles for article (PubMed ID: 30851217)
41. Multicomorbidity of chronic diseases and substance use disorders and their association with hospitalization: Results from electronic health records data.
Wu LT; Zhu H; Ghitza UE
Drug Alcohol Depend; 2018 Nov; 192():316-323. PubMed ID: 30312893
[TBL] [Abstract][Full Text] [Related]
42. Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders.
García-Marchena N; Barrera M; Mestre-Pintó JI; Araos P; Serrano A; Pérez-Mañá C; Papaseit E; Fonseca F; Ruiz JJ; Rodríguez de Fonseca F; Farré M; Pavón FJ; Torrens M
PLoS One; 2019; 14(3):e0213791. PubMed ID: 30870525
[TBL] [Abstract][Full Text] [Related]
43. Trends in documented cannabis use disorder among hospitalized adult epilepsy patients in the United States.
Lekoubou A; Fox J; Bishu KG; Ovbiagele B
Epilepsy Res; 2020 Jul; 163():106341. PubMed ID: 32361206
[TBL] [Abstract][Full Text] [Related]
44. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.
Green AI; Tohen MF; Hamer RM; Strakowski SM; Lieberman JA; Glick I; Clark WS;
Schizophr Res; 2004 Feb; 66(2-3):125-35. PubMed ID: 15061244
[TBL] [Abstract][Full Text] [Related]
45. Impact of implementing a tobacco and recreational nicotine-free policy and enhanced treatments on programmatic and patient-level outcomes within a residential substance use disorder treatment program.
Hemmy Asamsama O; Miller SC; Silvestri MM; Bonanno C; Krondilou K
J Subst Abuse Treat; 2019 Dec; 107():44-49. PubMed ID: 31757264
[TBL] [Abstract][Full Text] [Related]
46. Substance use disorders and the risk of suicide mortality among men and women in the US Veterans Health Administration.
Bohnert KM; Ilgen MA; Louzon S; McCarthy JF; Katz IR
Addiction; 2017 Jul; 112(7):1193-1201. PubMed ID: 28301070
[TBL] [Abstract][Full Text] [Related]
47. Persistence/recurrence of and remission from DSM-5 substance use disorders in the United States: Substance-specific and substance-aggregated correlates.
McCabe SE; West BT; Strobbe S; Boyd CJ
J Subst Abuse Treat; 2018 Oct; 93():38-48. PubMed ID: 30126540
[TBL] [Abstract][Full Text] [Related]
48. Correlates of specialty substance use treatment among adults with opioid use disorders.
Romo E; Ulbricht CM; Clark RE; Lapane KL
Addict Behav; 2018 Nov; 86():96-103. PubMed ID: 29551551
[TBL] [Abstract][Full Text] [Related]
49. Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: A population-based analysis in the United States.
Garg A; Papagermanos V; Midura M; Strunk A; Merson J
J Am Acad Dermatol; 2018 Sep; 79(3):495-500.e1. PubMed ID: 29499293
[TBL] [Abstract][Full Text] [Related]
50. Relationship of Cannabis Use Disorder and Irritable Bowel Syndrome (IBS): An Analysis of 6.8 Million Hospitalizations in the United States.
Patel RS; Goyal H; Satodiya R; Tankersley WE
Subst Use Misuse; 2020; 55(2):281-290. PubMed ID: 31573379
[No Abstract] [Full Text] [Related]
51. Survival Probabilities and Predictors of Major Depressive Episode Incidence Among Individuals With Various Types of Substance Use Disorders.
Hassan AN; Le Foll B
J Clin Psychiatry; 2021 Jul; 82(5):. PubMed ID: 34320696
[No Abstract] [Full Text] [Related]
52. Risk factors for COVID-19 among persons with substance use disorder (PWSUD) with hospital visits - United States, April 2020-December 2020.
Board AR; Kim S; Park J; Schieber L; Miller GF; Pike J; Cremer LJ; Asher A
Drug Alcohol Depend; 2022 Mar; 232():109297. PubMed ID: 35033956
[TBL] [Abstract][Full Text] [Related]
53. Genetic liability for substance use associated with medical comorbidities in electronic health records of African- and European-ancestry individuals.
Hartwell EE; Merikangas AK; Verma SS; Ritchie MD; ; Kranzler HR; Kember RL
Addict Biol; 2022 Jan; 27(1):e13099. PubMed ID: 34611967
[TBL] [Abstract][Full Text] [Related]
54. Association Patterns of Antisocial Personality Disorder across Substance Use Disorders.
Low A; Stiltner B; Nunez YZ; Adhikari K; Deak JD; Pietrzak RH; Kranzler HR; Gelernter J; Polimanti R
medRxiv; 2023 Sep; ():. PubMed ID: 37745497
[TBL] [Abstract][Full Text] [Related]
55. Symptoms of anxiety, depression, and borderline personality in alcohol use disorder with and without comorbid substance use disorder.
Howe LK; Fisher LR; Atkinson EA; Finn PR
Alcohol; 2021 Feb; 90():19-25. PubMed ID: 33232791
[TBL] [Abstract][Full Text] [Related]
56. Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States.
Hartzler B; Dombrowski JC; Crane HM; Eron JJ; Geng EH; Christopher Mathews W; Mayer KH; Moore RD; Mugavero MJ; Napravnik S; Rodriguez B; Donovan DM
AIDS Behav; 2017 Apr; 21(4):1138-1148. PubMed ID: 27738780
[TBL] [Abstract][Full Text] [Related]
57. Alcohol, Cannabis, and Opioid Use Disorders, and Disease Burden in an Integrated Health Care System.
Bahorik AL; Satre DD; Kline-Simon AH; Weisner CM; Campbell CI
J Addict Med; 2017; 11(1):3-9. PubMed ID: 27610582
[TBL] [Abstract][Full Text] [Related]
58. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
Wiercigroch D; Sheikh H; Hulme J
Subst Abuse Treat Prev Policy; 2020 Jan; 15(1):4. PubMed ID: 31931831
[TBL] [Abstract][Full Text] [Related]
59. Alcohol, marijuana, and opioid use disorders: 5-Year patterns and characteristics of emergency department encounters.
Bahorik AL; Satre DD; Kline-Simon AH; Weisner CM; Young-Wolff KC; Campbell CI
Subst Abus; 2018 Jan; 39(1):59-68. PubMed ID: 28723312
[TBL] [Abstract][Full Text] [Related]
60. DSM-5 substance use disorders among adult primary care patients: Results from a multisite study.
Wu LT; McNeely J; Subramaniam GA; Brady KT; Sharma G; VanVeldhuisen P; Zhu H; Schwartz RP
Drug Alcohol Depend; 2017 Oct; 179():42-46. PubMed ID: 28753480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
